Childhood Adversity Raises the Risk of Depression That Resists Treatment

Depression that does not respond to standard treatment affects roughly one in three patients with major depressive disorder. For clinicians, predicting which patients will struggle with treatment resistance - and why - remains one of the field's most pressing problems. A new cohort study points toward an answer that begins decades before the first prescription is written.

The research, published in JAMA Network Open, found that exposure to adverse childhood experiences (ACEs) - a category that includes abuse, neglect, household dysfunction, and other early-life traumas - was associated with a significantly higher risk of developing treatment-resistant depression later in life. The finding held even after accounting for unmeasured familial confounding, a methodological step that strengthens the case for a direct link.

Beyond simple correlation

Studies connecting childhood adversity to adult depression are not new. What makes this work notable is its approach to confounding. Families share both genes and environments. Children raised in the same household may experience similar adversities but also inherit similar genetic predispositions to depression. Untangling these threads has been a persistent challenge in ACE research.

The study, led by corresponding author Ying Xiong, PhD, MMedSc, at the Karolinska Institute in Sweden, used sibling comparisons to control for shared familial factors. By examining outcomes among siblings who experienced different levels of childhood adversity, the researchers could isolate the contribution of ACEs more cleanly than studies that compare unrelated individuals.

The association between ACE exposure and treatment-resistant depression persisted in these within-family analyses. That is, even among siblings who share the same genetic background and household environment, those with greater ACE exposure were more likely to develop depression that did not respond to standard treatments.

What treatment resistance looks like

Treatment-resistant depression is typically defined as major depressive disorder that does not adequately improve after two or more trials of antidepressant medication at adequate doses and duration. For patients, it means months or years of trying different medications, dosage adjustments, and combination therapies, often with limited relief.

The mechanisms linking childhood adversity to treatment resistance are not fully understood. Chronic stress during development may alter the hypothalamic-pituitary-adrenal (HPA) axis, the brain's central stress-response system. It may affect inflammatory pathways or reshape neural circuits involved in mood regulation. These biological changes could make the brain less responsive to the pharmacological mechanisms that standard antidepressants rely on.

But the study does not test specific mechanisms. It establishes an association - a strong and well-controlled one, but an association nonetheless.

Clinical implications and practical limits

The authors argue their findings highlight the importance of two things: preventing ACEs in the first place, and incorporating ACE history into clinical assessment when treating depression. If a patient's depression has roots in early-life trauma, clinicians might consider earlier escalation to alternative treatments, combination approaches, or trauma-focused psychotherapies rather than cycling through multiple antidepressant trials.

That said, the study has limitations worth noting. The cohort was drawn from Swedish registries, which provide excellent longitudinal data but represent a specific population with a particular healthcare system. Whether the same magnitude of association holds in populations with different healthcare access, cultural contexts, or definitions of treatment resistance is an open question.

ACE measurement in registry studies also tends to capture documented experiences - those that came to the attention of social services or healthcare systems. Undocumented adversity, which may be common among the most disadvantaged families, could lead to underestimation of the true effect.

The study cannot establish causation. Despite the sibling design, it remains possible that unmeasured individual-level factors - rather than ACEs themselves - drive the association. And the practical question of whether screening for ACEs in psychiatric settings actually improves outcomes has not been tested here.

Still, for clinicians facing a patient whose depression has not responded to the first or second medication, an ACE history may be a useful signal - not a diagnosis, but a prompt to think differently about the treatment plan.